Minerva endocrinology最新文献_第3页

Epicardial fat tissue in metabolically healthy and unhealthy obesity: culprit or bystander? 代谢健康与不健康肥胖的心外膜脂肪组织：罪魁祸首还是旁观者？

IF 2.5

Minerva endocrinology Pub Date : 2025-07-10 DOI: 10.23736/S2724-6507.25.04257-5

Giulia de Alteriis, Gabriella Pugliese, Carolina DI Somma, Andrea Falco, Giovanna Muscogiuri, Luigi Barrea, Daniela Laudisio, Francesca Zumbolo, Roberta Esposito, Martina Pucci, Valentina Cossiga, Filomena Morisco, Silvia Savastano

{"title":"Epicardial fat tissue in metabolically healthy and unhealthy obesity: culprit or bystander?","authors":"Giulia de Alteriis, Gabriella Pugliese, Carolina DI Somma, Andrea Falco, Giovanna Muscogiuri, Luigi Barrea, Daniela Laudisio, Francesca Zumbolo, Roberta Esposito, Martina Pucci, Valentina Cossiga, Filomena Morisco, Silvia Savastano","doi":"10.23736/S2724-6507.25.04257-5","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04257-5","url":null,"abstract":"Background: A uniform definition distinguishing metabolically healthy obesity (MHO) from metabolically unhealthy obesity (MUO) is lacking. MUO is characterized by higher liver and visceral fat than MHO. Epicardial fat tissue (EFT) is an index of cardiac adiposity strongly associated with risk of cardiovascular events. This study aimed to further define the MHO/MUO status by evaluating EFT and hepatic steatosis/fibrosis indices in adults presenting visceral obesity.Methods: In this monocentric, observational study, 56 patients (48 females; 43.8±13.1 years) were recruited. Clinical characteristics, anthropometric measurements, and metabolic parameters were evaluated. Hepatic fibrosis and steatosis were assessed by Fibroscan (502Touch, Echosense). EFT thickness was assessed by transthoracic echocardiography (GE Vivid E95 system). EFT thickness values of 9.5 mm in men and 7.5 mm in women were used as predictors of the metabolic syndrome (MetS).Results: Patients with MUO had significantly higher steatosis/fibrosis indices and EFT values than the MHO group (P<0.001). EFT values above the cut-off were found in 82.1% of MUO, but also in 42.9% of MHO. At ROC analysis, the specificity and sensitivity of the EFT cut-off point to predict MUO phenotype combined with hypertension, 60-min post load plasma glucose, and adiponectin, were 98.6% and 92.0%, respectively.Conclusions: As EFT thickness values above the predictive threshold for MetS were found in about half of MHO, the MHO/MUO classification may not correctly identify the cardiovascular risk of MHO. Further clinical evidence is needed to confirm EFT thickness as potential additional marker for MHO/MUO phenotypic differentiation.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic metabolic acidosis of diabetes (CMAD): clinical features, diagnosis, and therapeutic potentials of pH correction. 糖尿病慢性代谢性酸中毒（CMAD）：临床特征、诊断和pH校正的治疗潜力。

IF 2.5

Minerva endocrinology Pub Date : 2025-07-10 DOI: 10.23736/S2724-6507.25.04230-7

Hayder A Giha, Mai S Sater, Ali A Al Qarni

{"title":"Chronic metabolic acidosis of diabetes (CMAD): clinical features, diagnosis, and therapeutic potentials of pH correction.","authors":"Hayder A Giha, Mai S Sater, Ali A Al Qarni","doi":"10.23736/S2724-6507.25.04230-7","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04230-7","url":null,"abstract":"pH changes are a cardinal feature in metabolic disorders. Based on published literature, chronic metabolic acidosis is a major finding in type 2 diabetes (T2D), which is recently described as CMAD (chronic metabolic acidosis of T2D). Several disorders characterized by overt metabolic acidosis are recognized as T2D co-morbidities or are dual risk factors that pertain to their unique signs and symptoms in T2D. Over time, many terms were used for chronic metabolic acidosis (CMA) in different disorders. However, the lack of a unified term for CMA, delayed the recognition of CMAD as a prime feature of T2D, and the setting of the diagnostic criteria and management protocol for this disorder. Other than the classical diabetic complications, CMAD contributes to non-classical organ-specific local diabetic complications. Here we described the likely clinical features of CMAD in general, such as fatigue, tiredness, cramps, and aches, as well as organ/system-specific symptoms of T2D related to the liver, skeletal muscles, bones and joints, lungs, nervous system, eyes, kidneys and urinary tract, oral cavity and teeth, gastrointestinal tract, immune system, and skin. Diagnostic criteria and confirmatory tests are enlisted together with the laboratory tools used for pH estimation in different body compartments. Finally, a management protocol is proposed, which covers: 1) lifestyle (exercise, stress management); 2) nutrition (drinks, foods, and supplements); and 3) therapeutic pH correction: general proton pump inhibitor (PPI) and alkaline minerals; and organ-specific therapies with different modalities of action. In addition, the therapeutic potentials of nanomedicine and immune and gene therapies for pH correction are raised.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reporting on the real-world safety and effectiveness of oral semaglutide in improving glycemic control and reducing cardiovascular risk: a letter to the editor. 报告口服西马鲁肽在改善血糖控制和降低心血管风险方面的实际安全性和有效性：致编辑的一封信。

IF 2.5

Minerva endocrinology Pub Date : 2025-07-02 DOI: 10.23736/S2724-6507.25.04395-7

Antonio M Labate, Giancarla Meregalli, Francesca Nicolì, Giulia Ongis, Lorenzo Moretti, Emanuele Allemand, Maria L Spina, Provvidenza Villari

引用次数: 0

Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes. 2型糖尿病药物治疗的疗效机制：微生物组的作用。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-30 DOI: 10.23736/S2724-6507.25.04306-4

Yushan Li, Ziling He, Chunyan Li, Jing Huang, Zheng Yu

{"title":"Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes.","authors":"Yushan Li, Ziling He, Chunyan Li, Jing Huang, Zheng Yu","doi":"10.23736/S2724-6507.25.04306-4","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04306-4","url":null,"abstract":"The gut microbiota plays a crucial role in the human body and has an impact on the physiological function of the host. In particular, changes in the gut microbiota are especially pronounced in patients with type 2 diabetes. There is ample evidence that glucose-lowering drugs exert their therapeutic effects precisely through their interactions with the gut microbiota, but there is a lack of summarization. An overall comparison of the effects of each hypoglycemic agent on the gut flora can provide new inspiration for combinations. In this paper, we selected several representative glucose-lowering drugs, such as metformin, sodium-dependent glucose transporters 2 inhibitors (dapagliflozin), glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide), and the traditional Chinese medicine (berberine), and illustrated how they can affect the disease process by regulating metabolic homeostasis, immune response, and gut barrier. We found that each of these four hypoglycemic agents can have conflicting effects on the gut flora depending on the timing and mode of administration. Meanwhile, the potential impact of gut microbiota on drug safety is explored, and an outlook for the optimization of future type 2 diabetes treatment regimens is presented.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose-response relationship between circulating growth differentiation factor-15 and diabetes: a systematic review and meta-analysis. 循环生长分化因子-15与糖尿病的剂量-反应关系：系统综述和荟萃分析。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-25 DOI: 10.23736/S2724-6507.25.04240-X

Jianshu Gao, Hongli Liu, Zhongwei Zhou, Sanqiang Hu

{"title":"Dose-response relationship between circulating growth differentiation factor-15 and diabetes: a systematic review and meta-analysis.","authors":"Jianshu Gao, Hongli Liu, Zhongwei Zhou, Sanqiang Hu","doi":"10.23736/S2724-6507.25.04240-X","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04240-X","url":null,"abstract":"Introduction: Increasing evidence suggests that circulating growth differentiation factor-15 (GDF-15) may serve as a predictor of unfavorable clinical outcomes, but limited information is available on its relationship to diabetes risk. This meta-analysis was designed to evaluate quantitatively circulating GDF-15 in relation to diabetes prevalence.Evidence acquisition: Our search encompassed the PubMed, Embase, and Web of Science databases from the inception dates to April 2024. Studies that provided data on diabetes prevalence across at least three distinct GDF-15 categories were eligible for inclusion in this meta-analysis.Evidence synthesis: There were 27 independent studies from 25 articles included in this meta-analysis, involving 56,969 participants, 12,795 of whom were diabetic patients. The two-class meta-analysis showed participants with higher GDF-15 level had a higher diabetes prevalence [odds ratios (OR) 2.53, 95% confidence interval (CI) 2.09-3.05) than those with lower GDF-15 level. The diabetes prevalence increased by 63% (OR 1.63, 95% CI 1.47-1.80) when GDF-15 concentration was increased by 1 ng/mL, according to the dose-response meta-analysis. Nevertheless, the dose-response curve showed diabetes prevalence increased nonlinearly with increasing GDF-15 concentration (P nonlinearity <0.001), with a plateau or even a slight decrease after approximately 5.7 ng/mL of GDF-15 concentration. In the pooled estimates, considerable heterogeneity was observed and meta-regression analysis facilitated the interpretation of heterogeneity, which revealed significant correlations between diabetes prevalence and sample sizes (P<0.001) and hypertension prevalence (P=0.025).Conclusions: This meta-analysis reveals a positive and non-linear relationship between circulating GDF-15 and diabetes prevalence, which plateaus or slightly declines after reaching a certain level of GDF-15.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic health and quality of life in patients with Polycystic Ovary Syndrome: a cross-sectional study. 多囊卵巢综合征患者的代谢健康和生活质量：一项横断面研究

IF 2.5

Minerva endocrinology Pub Date : 2025-06-18 DOI: 10.23736/S2724-6507.25.04245-9

Konstantin Hofmann, Susanne Singer, Susanne Theis, Annette Hasenburg, Roxana Schwab, Christine Skala

{"title":"Metabolic health and quality of life in patients with Polycystic Ovary Syndrome: a cross-sectional study.","authors":"Konstantin Hofmann, Susanne Singer, Susanne Theis, Annette Hasenburg, Roxana Schwab, Christine Skala","doi":"10.23736/S2724-6507.25.04245-9","DOIUrl":"https://doi.org/10.23736/S2724-6507.25.04245-9","url":null,"abstract":"Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder that can result in reduced health-related quality of life (HRQOL). Metabolic changes, particularly insulin resistance and obesity, play a significant role in PCOS pathogenesis. This study examined associations between metabolic factors and HRQOL in PCOS patients.Methods: A cross-sectional study of 77 patients was conducted at University Medical Center Mainz. At the time of inclusion in the study, patients had to be over 18 and not undergoing active PCOS therapy. A desire to conceive or fertility therapy led to exclusion. Participants were over 18, not undergoing PCOS therapy, and not seeking pregnancy. HRQOL and psychological distress were measured using the Modified-PCOS-Questionnaire (MPCOSQ) and Hospital Anxiety and Depression Scale (HADS). Linear regression analyses assessed associations between metabolic markers and HRQOL, with significant variables included in a multivariate model.Results: Worsening metabolic markers were linked to lower HRQOL, especially in body hair and menstrual symptom domains. Markers such as HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) levels (P=0.040), elevated VAI (Visceral Adiposity Index) (P=0.035), and increased FLI (Fatty Liver Index) (P=0.023) were associated with diminished HRQOL. In the multivariate regression analysis, only a BMI ≥25kg/m2 (P=0.001) emerged as a statistically significant value.Conclusions: This study showed a significant correlation between metabolic markers, including BMI, FLI, VAI, HOMA-IR, and HRQOL in PCOS patients. BMI was the most meaningful predictor for HRQOL. BMI, despite being controversial and prone to errors, may be more indicative of HRQOL than specific metabolic markers.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma. 斑马鱼胚胎癌细胞异种移植作为肾上腺皮质癌药物筛选的实验工具。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-01 Epub Date: 2025-02-25 DOI: 10.23736/S2724-6507.24.04270-2

Mariangela Tamburello, Andrea Abate, Sandra Sigala

{"title":"Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma.","authors":"Mariangela Tamburello, Andrea Abate, Sandra Sigala","doi":"10.23736/S2724-6507.24.04270-2","DOIUrl":"10.23736/S2724-6507.24.04270-2","url":null,"abstract":"Despite the widespread use of murine models in in-vivo experiments, the zebrafish (Danio rerio) offers unique advantages that make it a versatile and faster preclinical model for drug screening, particularly for adrenocortical carcinoma (ACC), a rare malignancy with limited preclinical models that reflect patient heterogeneities. Over the past decade, significant progress has been made with models like cell lines, organoids, and murine models, which are crucial for advancing disease understanding and treatment development. However, recent reviews have overlooked zebrafish model for ACC. This mini review aims to fill this gap by detailing the advancements of the zebrafish model in ACC research. Recent studies have utilized zebrafish embryos xenografted with ACC cells as a novel approach to studying drug effects on tumor growth and metastasis, consistent with studies regarding other tumors. Specifically, it was demonstrated the ability of abiraterone acetate, trabectedin and progesterone to significantly reduce the tumor area at non-toxic-concentrations. Interestingly, this model allowed to confirm in vivo that metastasis-derived cells were able to metastasize and that trabectedin and progesterone reduced the rate of embryos with metastasis. One more study showed that metastasis formation was significantly reduced in H295R/TR-SF-1-xenografted embryos after fascin1 knock-out or inhibition with G2-044. Even with some limitations, the zebrafish xenografts offer a suitable and expeditious animal model for the screening of potentially effective drugs, identification of dose toxicity, and determination of the most promising compounds for more advanced preclinical phases, especially in rare diseases with limited therapeutic options such as ACC.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"182-193"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine for type 2 diabetes during COVID-19 pandemic: experience from a tertiary diabetes center. COVID-19 大流行期间 2 型糖尿病的远程医疗：一家三级糖尿病中心的经验。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-01 Epub Date: 2024-01-29 DOI: 10.23736/S2724-6507.23.04096-4

Silvia Angelino, Paola Caruso, Miriam Longo, Mariluce Barrasso, Filomena Castaldo, Alessandro Pontillo, Stefania Arena, Annarita Palmieri, Giuseppe Bellastella, Maria I Maiorino, Katherine Esposito

{"title":"Telemedicine for type 2 diabetes during COVID-19 pandemic: experience from a tertiary diabetes center.","authors":"Silvia Angelino, Paola Caruso, Miriam Longo, Mariluce Barrasso, Filomena Castaldo, Alessandro Pontillo, Stefania Arena, Annarita Palmieri, Giuseppe Bellastella, Maria I Maiorino, Katherine Esposito","doi":"10.23736/S2724-6507.23.04096-4","DOIUrl":"10.23736/S2724-6507.23.04096-4","url":null,"abstract":"Background: Telemedicine was largely employed during COVID-19 pandemic to guarantee continuity of care in a period of dramatic reduction of face-to-face visits. The aim of this study was to describe the clinical characteristics of a cohort of patients with type 2 diabetes followed by tele-visits and to evaluate the changes in the glyco-metabolic control during a 12-month follow-up.Methods: This retrospective observational study included 136 adults aged >18 years with at least three tele-visits over a 12-month follow-up period, in a Diabetes Center of the Southern Italy, from April 2020 to March 2022. Data related to glycemic and lipid profile, therapy, presence of micro or macrovascular complications, and other clinical features were extracted at three time points, at first visit (T0), after 6 months (T1) and after 12 months (T2).Results: Mean diabetes duration and median HbA1c values were 11.6 years and 7.0%, respectively. Thirty-eight participants (27.9%) presented macro- or microvascular complications. Glycemic control remained stable over time, without clinically significant changes of HbA<inf>1c</inf> (T0 vs. T1 vs. T2, median [IQR], 7.0 [6.2-7.3], 6.6 [6.0-7.5], 6.9 [6.2-7.5], P=0.095) and fasting glucose. Lipid profile slightly improved, although without significant clinical change. Glucose lowering therapy was modified in 84 patients (61.8%) and remained unchanged in 52 patients (38.2%) during the follow-up. No participant in the study developed any complications during the 12-month follow-up.Conclusions: People with type 2 diabetes followed by telemedicine were adults with fair glucose control generally free from chronic complications, whose diabetes control did not worsen during a 12-month follow-up.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"163-171"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insulin resistance is associated with increased circulating lipocalin-2 levels in polycystic ovary syndrome: a systematic review and meta-analysis. 胰岛素抵抗与多囊卵巢综合征患者循环脂联素-2水平升高有关：系统综述和荟萃分析。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-01 Epub Date: 2023-01-16 DOI: 10.23736/S2724-6507.22.03926-4

Seshadri R Varikasuvu, Faustino R Pérez-López, Anirban Ganguly, Subodh Kumar, Anandakumar Pandi, Jitender Prasad, Vanita Lal DAS

{"title":"Insulin resistance is associated with increased circulating lipocalin-2 levels in polycystic ovary syndrome: a systematic review and meta-analysis.","authors":"Seshadri R Varikasuvu, Faustino R Pérez-López, Anirban Ganguly, Subodh Kumar, Anandakumar Pandi, Jitender Prasad, Vanita Lal DAS","doi":"10.23736/S2724-6507.22.03926-4","DOIUrl":"10.23736/S2724-6507.22.03926-4","url":null,"abstract":"Introduction: This meta-analysis was conducted to compare the circulating lipocalin-2 levels in polycystic ovary syndrome (PCOS).Evidence acquisition: Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. The subgroup analysis based on the Body Mass Index (BMI) and the homeostasis model assessment-estimated insulin resistance (HOMA-IR) was conducted. Meta-analysis of correlations and meta-regression were performed for the associations of lipocalin-2 with the metabolic and hormonal covariates. The funnel plot analysis was used for publication bias.Evidence synthesis: The combined effect size including a total of 13 studies showed no significant difference in lipocalin-2 levels between PCOS and control groups. However, the subgroup meta-analysis based on insulin resistance showed a significant difference in the circulatory lipocalin-2 levels in PCOS as compared to controls in both HOMA-IR<3 (SMD=-1.15, Z=2.42, P=0.02) and HOMA-IR>3 subgroups (SMD=0.91, Z=2.43, P=0.02).Conclusions: There were significant associations of lipocalin-2 with age, BMI, estrogen and hyperandrogenism in PCOS. Lipocalin-2 level alterations in PCOS are associated to insulin resistance. More is the insulin resistance, higher is the lipocalin-2 level in PCOS as compared to controls.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"194-200"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10531079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of the April-June 2025 issue. 2025年4月至6月期的亮点。

IF 2.5

Minerva endocrinology Pub Date : 2025-06-01 DOI: 10.23736/S2724-6507.25.04394-5

Giovanni Vitale

引用次数: 0